Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 4 1

Status

Recruiting 2Not yet recruiting 1Enrolling by invitation 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 2315Neoplasms 1678Prostatic Neoplasms 1178Lung Neoplasms 908Colorectal Neoplasms 873Carcinoma, Non-Small-Cell Lung 848Leukemia, Myeloid, Acute 587Pancreatic Neoplasms 568Multiple Myeloma 542Carcinoma, Hepatocellular 510Brain Neoplasms 509Neoplasm Metastasis 456Head and Neck Neoplasms 454Melanoma 410Ovarian Neoplasms 404Glioblastoma 397Precursor Cell Lymphoblastic Leukemia-Lymphoma 390Stomach Neoplasms 370Uterine Cervical Neoplasms 355Squamous Cell Carcinoma of Head and Neck 355Rectal Neoplasms 336Recurrence 332Hematologic Neoplasms 323Sarcoma 322Colonic Neoplasms 316Lymphoma 310Triple Negative Breast Neoplasms 284Urinary Bladder Neoplasms 279Glioma 277Carcinoma, Renal Cell 277

Interventions

Specimen Handling 1Medical Marijuana 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × Pancreatic Cancer Non-resectable × 1 year × Clear all
NCT07386704 2026-02-04

Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer

Peking University First Hospital

Phase 2 Enrolling by invitation
30 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT07302841 2025-12-24

Tunlametinib + AG + Cetuximab β as First-Line Therapy for Advanced Pancreatic Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 4 Not yet recruiting
28 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT07271823 2025-12-09

Establishment of a Predictive Model for Immunotherapy Response in Pancreatic Cancer

Zhejiang Cancer Hospital

Active not recruiting
100 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT06605430 2025-07-29

CanPan-C

HealthPartners Institute

Phase 2 Recruiting
64 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

NCT06937996 2025-06-17

Outcomes of Ablation of Unresectable Pancreatic Cancer Using the NanoKnife Irreversible Electroporation System-

Englewood Hospital and Medical Center

Recruiting
25 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡